(Q37972758)

26 August 2017

title

Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice (English)

1 reference

26 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

1 reference

1

Christophe Hézode

0 references

author name string

Christophe Hézode

series ordinal

1

1 reference

26 August 2017

language of work or name

1 reference

1 February 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

32 Suppl 1

1 reference

26 August 2017

page(s)

32-38

1 reference

Global epidemiology of hepatitis C virus infection

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02707.X

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02707.X

Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02707.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02707.X

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02707.X

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02707.X

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02707.X

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02707.X

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02707.X

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02707.X

Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02707.X

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02707.X

Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02707.X

Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02707.X

Drug rash with eosinophilia and systemic symptoms due to telaprevir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02707.X

Initial management of a major burn: II--assessment and resuscitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02707.X

Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02707.X

New direct-acting antivirals' combination for the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02707.X

10.1111/J.1478-3231.2011.02707.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference